Advanced Infliximab Model Now Available from DoseMe
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Lynx.MD Leveraged for Study on Infliximab Optimization for IBD to be Presented
Pfizer`s Biologic IIxifi (Infliximab) Receives Approval in the U.S.
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA
Celltrion`s Biologic Zymfentra (infliximab) Receives Approval in the U.S.
Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease
A Pennsylvania federal judge on Wednesday cemented a $25 million settlement in a class action suit alleging Johnson & Johnson blocked biosimilar competition to its immunosuppressive drug Remicade.
A Pennsylvania federal judge on Wednesday cemented a $25 million settlement in a class action suit alleging Johnson & Johnson blocked biosimilar competition to its immunosuppressive drug Remicade.
Celltrion has announced that it has finalised its submission of a biologics license application for the subcutaneous version of a biosimilar to anti-inflammatory medicine Remicade, to be submitted to the FDA.